Skip to main content

Medical Oncology Clinic

The Institut Bordet Medical Oncology Clinic has a number of roles:

  • diagnosis and therapeutic care of patients with solid tumours
  • overseeing administration of cancer medication for in-patients and out-patients
  • monitoring patients during and after their treatment.

The Clinic takes a multidisciplinary approach. Therapeutic decisions are made in consultation with other specialist doctors and healthcare professionals involved in the patient’s care.
The aim is that patients should be monitored in all respects, including psychologically.

The Medical Oncology Clinic forms an integral part of the Department of Oncological Medicine. It is also very active in clinical research (particularly in the development of new medication) and translational research. At the Clinic, research is integrated into the care provided, enabling patients to benefit from the latest diagnostic and therapeutic advances, well before these become part of clinical routine.

Research projects

Project 1

AURORA Programme aimed at understanding the molecular characteristics of recurrent and metastatic breast cancer early in the evolution of metastatic disease.

Project 2

CHARACTERIZATION OF ENDOCRINE RESISTANT Luminal Breast Cancer using spatial transcriptomics AND epigenetic ANALYSIS. 
  • Project leaders : Christos Sotiriou, Françoise Rothé and Mattia Rediti
  • Collaborations : 
    - Dr François Fuks, Laboratory of Cancer Epigenetics, ULB-Cancer Research Center (U-CRC), Université libre de Bruxelles
    - Prof Lundeberg at the SciLife laboratory, Stockholm, Sweden
    - Dr Frédérick Libert, ULB/VUB Brightcore sequencing facility

Project 3

ZENITH: A PHASE 2 STUDY OF ZEN003694 IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER (BRCA1 OR BRCA2 NON MUTATED)
  • Project leader : Philippe Aftimos 
  • Collaborations : International clinical study
  • Funding (or) Support : Zenith Epigenetics Ltd.

Project 4

MULTICENTRIC PHASE II SINGLE-ARM STUDY OF NIVOLUMAB IN PATIENTS WITH TYPE B3 THYMOMA AND THYMIC CARCINOMA PREVIOUSLY TREATED WITH CHEMOTHERAPY
  • Project leader : Thierry Berghmans
  • Collaborations : International clinical study
  • Funding (or) Support : EORTC

Project 5

AURA : Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers

Project 6

MIME-A Abémaciclib
Multiorgan Metabolic imaging response assessment of Abemaciclib

Our team

Head of the Medical Oncology Clinic
Pr A. Awada

Solid Tumours / New Innovative drugs
Pr A. AwadaDr Ph. AftimosDr N. Kotecki

Solid and RareTumours
Pr A. AwadaDr Ch. Jungels

Breast Oncology
Pr M. PiccartDr D. de Valeriola
Dr Ph. AftimosDr A. Gombos
Pr Ch. SotiriouDr E. de Azambuja
Dr M. IgnatiadisDr F. Lebrun 
Dr L. BuisseretDr L. Polastro
Pr A. DrowartDr D. t’Kint de Roodenbeke

Oncogeriatrics 
Dr L. Dal LagoPr Th. Pepersack (geriatrician)

Cervico-facial Oncology  
Dr Y. Lalami

Skin Tumour Oncology                
Dr J. Kerger / Pr A. Awada
Pr A. Drowart
Dr M. Suppa

Digestive Oncology / Gastroenterology / Endoscopy
Dr A. HendliszDr A. Deleporte
Dr F. Sclafani

Gynaecological Oncology
Dr J. KergerDr L. Polastro
Dr F. LebrunPr A. Drowart

Thoracic Oncology
Pr Th. Berghmans

Urogenital, Bone and Soft Tissue Oncology
Dr Th. Gil,
Dr Ch. Jungels (sarcomas)
Dr N. Martínez-Chanza (urogenital tumors)

Dr S. Sideris (urogenital tumors)

Oncological Day Hospital
Dr D. de Valeriola
Dr Y. Lalami, Dr L. Polastro

Oncogenetics
Dr D. t’Kint de Roodenbeke

Psychooncology
Pr D. Razavi, Dr G. StefosDr X. Bondenet

Supportive and Palliative Cares / Pain Clinic
Pr D. Lossignol, Dr I. Libert, Pr A. Drowart (mobile unite)

Consultants :    
Pr J. Klastersky (internal medicine/oncology)
Pr B. Desmarez (gastroenterology/endoscopy)
Dr Z. El Ali (medical oncology)
Dr E. Girard (oncologie médicale/digestive)
Dr P. Gkolfakis (gastroentérologie/endoscopie)
Dr Y. Gökburun (gastroenterology/medical oncology)
Dr D. Levacq (medical oncology/oncogenetics)
Dr A. Lepida (gastroenterology/hepatology)
Dr H. Louis (gastroenterology/digestive functional disorders)
Dr F. Mana (gastroenterology/endoscopy)
Pr A. Van Gossum (endoscopy/gastroenterology/nutrition)

 Scientific publications

Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer.

Authors : Sonnenblick A, Salmon-Divon M, Salgado R, Dvash E, Pondé N, Zahavi T, Salmon A, Loibl S, Denkert C, Joensuu H, Ameye L, Van den Eynden G, Kellokumpu-Lehtinen PL, Azaria A, Loi S, Michiels S, Richard F, Sotiriou C
Year : 2020
Journal : Int J Cancer

Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.

Authors : Donskov F, Motzer RJ, Voog E, Hovey E, Grüllich C, Nott LM, Cuff K, Gil T, Jensen NV, Chevreau C, Negrier S, Depenbusch R, Bergmann L, Cornelio I, Champsaur A, Escudier B, Pal S, Powles T, Choueiri TK
Year : 2020
Journal : Eur J Cancer
Volume : 126
Pages : 1-10

Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer.

Authors : Pondé N, Amaye L, Lambertini M, Paesmans M, Piccart M, de Azambuja E
Year : 2020
Journal : Eur J Cancer
Volume : 126
Pages : 65-73

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.

Authors : Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, Patel A, DeCara J, Mitchell J, Harrison E, Moslehi J, Witteles R, Calabro MG, Orecchia R, de Azambuja E, Zamorano JL, Krone R, Iakobishvili Z, Carver J, Armenian S, Ky B, Cardinale D, Cipolla CM, Dent S, Jordan K
Year : 2020
Journal : Ann Oncol
Volume : 31
Pages : 171-190

Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice.

Authors : Bregni G, Akin Telli T, Camera S, Deleporte A, Moretti L, Bali AM, Liberale G, Holbrechts S, Hendlisz A, Sclafani F
Year : 2020
Journal : Cancer Treat Rev
Volume : 83
Pages : 101948